Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.9 Million USD | 15.36% |
| 2022 | -3.42 Million USD | 26.63% |
| 2021 | -4.67 Million USD | 5.87% |
| 2020 | -4.96 Million USD | 21.21% |
| 2019 | -6.29 Million USD | 21.34% |
| 2018 | -8 Million USD | 41.64% |
| 2017 | -13.72 Million USD | 44.02% |
| 2016 | -24.51 Million USD | 0.57% |
| 2015 | -24.65 Million USD | -95.15% |
| 2014 | -12.63 Million USD | 3.03% |
| 2013 | -13.02 Million USD | 9.13% |
| 2012 | -14.33 Million USD | 33.13% |
| 2011 | -21.44 Million USD | -3.61% |
| 2010 | -20.69 Million USD | -67.88% |
| 2009 | -12.32 Million USD | -19.17% |
| 2008 | -10.34 Million USD | -0.3% |
| 2007 | -10.31 Million USD | -42.8% |
| 2006 | -7.22 Million USD | -26.43% |
| 2005 | -5.71 Million USD | -57.23% |
| 2004 | -3.63 Million USD | -5.14% |
| 2003 | -3.45 Million USD | 51.39% |
| 2002 | -7.1 Million USD | -5367.62% |
| 2001 | -129.99 Thousand USD | -1030.48% |
| 2000 | -11.49 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -658.56 Thousand USD | -193.75% |
| 2024 Q1 | -270.59 Thousand USD | 55.25% |
| 2023 Q4 | -604.69 Thousand USD | 22.06% |
| 2023 Q2 | -800.2 Thousand USD | -2.3% |
| 2023 Q1 | -782.21 Thousand USD | -14.41% |
| 2023 FY | -2.92 Million USD | 14.66% |
| 2023 Q3 | -775.83 Thousand USD | 3.04% |
| 2022 Q1 | -1 Million USD | 18.18% |
| 2022 Q4 | -683.71 Thousand USD | -2.63% |
| 2022 Q3 | -666.18 Thousand USD | 38.2% |
| 2022 FY | -3.42 Million USD | 26.63% |
| 2022 Q2 | -1.07 Million USD | -7.79% |
| 2021 Q4 | -1.22 Million USD | -16.72% |
| 2021 Q2 | -1.22 Million USD | -3.5% |
| 2021 FY | -4.67 Million USD | 5.87% |
| 2021 Q3 | -1.04 Million USD | 14.3% |
| 2021 Q1 | -1.18 Million USD | 1.82% |
| 2020 Q1 | -1.44 Million USD | -18.62% |
| 2020 Q2 | -1.21 Million USD | 16.39% |
| 2020 Q4 | -1.2 Million USD | -9.14% |
| 2020 FY | -4.96 Million USD | 21.21% |
| 2020 Q3 | -1.1 Million USD | 9.0% |
| 2019 Q1 | -1.71 Million USD | 9.94% |
| 2019 Q2 | -1.83 Million USD | -7.55% |
| 2019 Q3 | -1.44 Million USD | 21.56% |
| 2019 Q4 | -1.22 Million USD | 15.38% |
| 2019 FY | -6.29 Million USD | 21.34% |
| 2018 Q2 | -2.32 Million USD | 19.83% |
| 2018 FY | -8 Million USD | 41.64% |
| 2018 Q4 | -1.89 Million USD | -39.87% |
| 2018 Q1 | -2.9 Million USD | -0.15% |
| 2018 Q3 | -1.35 Million USD | 41.71% |
| 2017 Q3 | -3.11 Million USD | 5.57% |
| 2017 Q4 | -2.9 Million USD | 6.98% |
| 2017 Q1 | -4.39 Million USD | 15.14% |
| 2017 FY | -13.72 Million USD | 44.02% |
| 2017 Q2 | -3.3 Million USD | 24.9% |
| 2016 Q2 | -5.04 Million USD | 40.7% |
| 2016 Q1 | -8.5 Million USD | 11.96% |
| 2016 Q3 | -5.77 Million USD | -14.51% |
| 2016 Q4 | -5.18 Million USD | 10.28% |
| 2016 FY | -24.51 Million USD | 0.57% |
| 2015 Q3 | -5.77 Million USD | -25.85% |
| 2015 Q1 | -4.62 Million USD | -1637.96% |
| 2015 FY | -24.65 Million USD | -95.15% |
| 2015 Q2 | -4.59 Million USD | 0.62% |
| 2015 Q4 | -9.66 Million USD | -67.22% |
| 2014 FY | -12.63 Million USD | 3.03% |
| 2014 Q4 | -265.85 Thousand USD | 93.05% |
| 2014 Q1 | -4.38 Million USD | -54.05% |
| 2014 Q2 | -4.15 Million USD | 5.06% |
| 2014 Q3 | -3.82 Million USD | 8.03% |
| 2013 FY | -13.02 Million USD | 9.13% |
| 2013 Q4 | -2.84 Million USD | 22.08% |
| 2013 Q3 | -3.65 Million USD | -11.05% |
| 2013 Q2 | -3.28 Million USD | -1.24% |
| 2013 Q1 | -3.24 Million USD | -44.1% |
| 2012 Q2 | -4.28 Million USD | -1.91% |
| 2012 FY | -14.33 Million USD | 33.13% |
| 2012 Q1 | -4.2 Million USD | 4.38% |
| 2012 Q4 | -2.25 Million USD | 37.31% |
| 2012 Q3 | -3.59 Million USD | 16.12% |
| 2011 Q4 | -4.39 Million USD | 41.14% |
| 2011 Q1 | -4.19 Million USD | 13.77% |
| 2011 FY | -21.44 Million USD | -3.61% |
| 2011 Q2 | -5.37 Million USD | -28.27% |
| 2011 Q3 | -7.47 Million USD | -38.89% |
| 2010 FY | -20.69 Million USD | -67.88% |
| 2010 Q4 | -4.86 Million USD | 34.63% |
| 2010 Q3 | -7.43 Million USD | -34.73% |
| 2010 Q2 | -5.52 Million USD | -92.53% |
| 2010 Q1 | -2.86 Million USD | 7.89% |
| 2009 Q4 | -3.11 Million USD | -10.3% |
| 2009 FY | -12.32 Million USD | -19.17% |
| 2009 Q1 | -2.38 Million USD | 15.08% |
| 2009 Q2 | -4 Million USD | -68.09% |
| 2009 Q3 | -2.82 Million USD | 29.52% |
| 2008 Q3 | -2.42 Million USD | 10.63% |
| 2008 Q4 | -2.8 Million USD | -15.66% |
| 2008 FY | -10.34 Million USD | -0.3% |
| 2008 Q1 | -2.39 Million USD | 10.25% |
| 2008 Q2 | -2.71 Million USD | -13.31% |
| 2007 FY | -10.31 Million USD | -42.8% |
| 2007 Q1 | -2.46 Million USD | -20.95% |
| 2007 Q2 | -2.39 Million USD | 2.86% |
| 2007 Q3 | -2.78 Million USD | -16.58% |
| 2007 Q4 | -2.66 Million USD | 4.27% |
| 2006 Q4 | -2.03 Million USD | 0.13% |
| 2006 FY | -7.22 Million USD | -26.43% |
| 2006 Q1 | -1.32 Million USD | 23.53% |
| 2006 Q2 | -1.82 Million USD | -38.35% |
| 2006 Q3 | -2.03 Million USD | -11.57% |
| 2005 Q3 | -1.21 Million USD | 30.02% |
| 2005 FY | -5.71 Million USD | -57.23% |
| 2005 Q4 | -1.72 Million USD | -42.51% |
| 2005 Q1 | -1.04 Million USD | -6.63% |
| 2005 Q2 | -1.73 Million USD | -66.22% |
| 2004 Q1 | -944.83 Thousand USD | -26.87% |
| 2004 FY | -3.63 Million USD | -5.14% |
| 2004 Q4 | -976.98 Thousand USD | 9.86% |
| 2004 Q3 | -1.08 Million USD | -25.25% |
| 2004 Q2 | -865.38 Thousand USD | 8.41% |
| 2003 Q1 | -954.66 Thousand USD | 86.33% |
| 2003 FY | -3.45 Million USD | 51.39% |
| 2003 Q3 | -952.74 Thousand USD | -18.66% |
| 2003 Q4 | -744.72 Thousand USD | 21.83% |
| 2003 Q2 | -802.89 Thousand USD | 15.9% |
| 2002 Q1 | -6594.00 USD | 94.34% |
| 2002 Q4 | -6.98 Million USD | -13251.82% |
| 2002 Q3 | -52.29 Thousand USD | -36.83% |
| 2002 Q2 | -38.21 Thousand USD | -479.6% |
| 2002 FY | -7.1 Million USD | -5367.62% |
| 2001 Q1 | -9999.00 USD | -149.99% |
| 2001 Q3 | -3400.00 USD | -340100.0% |
| 2001 Q2 | 1.00 USD | 100.01% |
| 2001 FY | -129.99 Thousand USD | -1030.48% |
| 2001 Q4 | -116.59 Thousand USD | -3329.24% |
| 2000 FY | -11.49 Thousand USD | 0.0% |
| 2000 Q2 | - USD | 100.0% |
| 2000 Q1 | -31.5 Thousand USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | 20 Thousand USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -117.252% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 42.487% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 83.744% |
| Nascent Biotech, Inc. | -2.22 Million USD | -30.108% |
| Rebus Holdings, Inc. | -664 Thousand USD | -336.935% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.545% |
| Qrons Inc. | -643.67 Thousand USD | -350.731% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -644.731% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 94.773% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -598.29% |
| Skye Bioscience, Inc. | -13.67 Million USD | 78.779% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.958% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 159.031% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1008.507% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.174% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1.78% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -88.877% |
| Mesoblast Limited | -84.14 Million USD | 96.552% |
| Marizyme, Inc. | -34.08 Million USD | 91.489% |
| Genus plc | 6.4 Million USD | 145.332% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 129.779% |
| Pharming Group N.V. | -4.87 Million USD | 40.543% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -46.05% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -211.5% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 65.254% |
| ContraFect Corporation | -56.88 Million USD | 94.9% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 36.302% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -106.938% |
| IMV Inc. | -38.67 Million USD | 92.498% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -5.468% |
| MultiCell Technologies, Inc. | -722.81 USD | -401284.873% |
| ONE Bio Corp. | 13.68 Million USD | 121.206% |
| Accustem Sciences Inc. | -3.74 Million USD | 22.559% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.082% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -500.596% |
| Q BioMed Inc. | -3.44 Million USD | 15.799% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 181.956% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -10.418% |
| Biomind Labs Inc. | -1 Million USD | -187.365% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.722% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 56.359% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -55.616% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -9586.331% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 81.718% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -50.121% |
| GB Sciences, Inc. | -1.42 Million USD | -104.24% |
| Alpha Cognition Inc. | -9.7 Million USD | 70.107% |
| HST Global, Inc. | -140.9 Thousand USD | -1958.982% |
| CSL Limited | 3.7 Billion USD | 100.078% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -157.91% |
| Halberd Corporation | -75.05 Thousand USD | -3765.756% |
| Enzolytics Inc. | -2.14 Million USD | -35.017% |
| Agentix Corp. | -1.37 Million USD | -111.499% |
| Resverlogix Corp. | -12.74 Million USD | 77.243% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 8.428% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.317% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -177.898% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 0.623% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -83.698% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 14.794% |
| AVAX Technologies, Inc. | 6.69 Million USD | 143.348% |
| Zenith Capital Corp. | -8.94 Million USD | 67.558% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.302% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -16553.751% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -18.162% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1591.597% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -44.718% |
| Kadimastem Ltd | -3.04 Million USD | 4.572% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -194.827% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -130.991% |
| BioStem Technologies, Inc. | -7.77 Million USD | 62.704% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1498.617% |
| LadRx Corporation | -3.82 Million USD | 24.123% |
| Cell Source, Inc. | -4.32 Million USD | 32.924% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -322.338% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -322.338% |
| NovAccess Global Inc. | -2.46 Million USD | -17.614% |
| Affymax, Inc. | -15.04 Million USD | 80.717% |
| Itoco Inc. | -919.14 Thousand USD | -215.648% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 31.549% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -159.272% |
| Mobile Lads Corp. | -554.55 Thousand USD | -423.172% |
| CytoDyn Inc. | -18.05 Million USD | 83.934% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -11426.619% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1218.283% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -413.747% |
| SYBLEU INC | -149.18 Thousand USD | -1844.798% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -59.732% |
| International Stem Cell Corporation | -663 Thousand USD | -337.594% |
| Bioxytran, Inc. | -3.82 Million USD | 24.054% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5411.493% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -14163.766% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 92.0% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -79.311% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -294.28% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 6.742% |
| Neutra Corp. | -229.48 Thousand USD | -1164.238% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 83.458% |
| PureTech Health plc | -146.19 Million USD | 98.016% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 86.5% |
| IXICO plc | -1.43 Million USD | -101.896% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 69.432% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.618% |
| CSL Limited | 3.81 Billion USD | 100.076% |
| Cellectis S.A. | -108.85 Million USD | 97.335% |